About Admune Therapeutics
Admune Therapeutics is a Healthcare company based in Danvers (United States) founded in 2013, and was acquired by Novartis in October 2015. Cytokine therapy drugs are developed for metastatic cancer treatment. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Admune Therapeutics, affiliated with Marine Polymer Technologies is a clinical-stage biotech company that develops cytokine therapy drugs for the treatment of metastatic cancers including melanoma, renal cell carcinoma, non-small cell lung cancers (NSCLC) and others. It has proprietary technologies for the production and use of heterodimeric IL-15Ra (hetIL-15) in cancer immunotherapy. The program is currently in phase 1 clinical trial through the National Cancer Institute at the National Institutes of Health. Admune was acquired by Novartis on Oct 21, 2015 and is currently operating as its subsidiary.
- Headquarters Danvers, United States
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website admune.com
- Acquired by Novartis (Oct 2015)
Investors in Admune Therapeutics
Admune Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Admune Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Admune Therapeutics
2 dated milestones of Admune Therapeutics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Admune Therapeutics is founded.
- Exit Acquired by Novartis.
Competitors of Admune Therapeutics
Admune Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Admune Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Admune Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Admune Therapeutics
Admune Therapeutics was founded in 2013.
Admune Therapeutics is headquartered in Danvers, United States. It is registered at Danvers, Massachusetts, United States.
Admune Therapeutics, affiliated with Marine Polymer Technologies is a clinical-stage biotech company that develops cytokine therapy drugs for the treatment of metastatic cancers including melanoma, renal cell carcinoma, non-small cell lung cancers (NSCLC) and others. It has proprietary technologies for the production and use of heterodimeric IL-15Ra (hetIL-15) in cancer immunotherapy. The program is currently in phase 1 clinical trial through the National Cancer Institute at the National Institutes of Health. Admune was acquired by Novartis on Oct 21, 2015 and is currently operating as its subsidiary.
Admune Therapeutics's top competitors include C4 Therapeutics, Erasca and MiRagen.
Admune Therapeutics has 1 investor. Key investors include Novartis.
Yes. Admune Therapeutics was acquired by Novartis in October 2015.
